Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

Item
http://www.wikidata.org/entity/Q48591297
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPARationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives.Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.Levodopa in the treatment of Parkinson's disease: an old drug still going strong.Continuous dopaminergic stimulation and novel formulations of dopamine agonists.Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.Non-human primate models of PD to test novel therapies.Changes in dynorphin immunoreactivity but unaltered density of enkephalin immunoreactive neurons in basal ganglia nuclei of genetically dystonic hamsters.Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.
P2860

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

Item
http://www.wikidata.org/entity/Q48591297
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Preproenkephalin mRNA expressi ...... omparison with L-DOPA therapy.
@en
Preproenkephalin mRNA expressi ...... omparison with L-DOPA therapy.
@nl
type
label
Preproenkephalin mRNA expressi ...... omparison with L-DOPA therapy.
@en
Preproenkephalin mRNA expressi ...... omparison with L-DOPA therapy.
@nl
prefLabel
Preproenkephalin mRNA expressi ...... omparison with L-DOPA therapy.
@en
Preproenkephalin mRNA expressi ...... omparison with L-DOPA therapy.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Preproenkephalin mRNA expressi ...... omparison with L-DOPA therapy.
@en
P2093
P304
P31
P356
10.1016/S0169-328X(97)00123-X
P433
P478
P50
P577
P698
P921